Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions.
Kim DW, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha SY, Duruisseaux M, Liu SV, Al Hallak MN, Umemoto K, Wesseler C, Cleary JM, Springfeld C, Neuzillet C, Joe A, Jauhari S, Ford J, Goto K. Kim DW, et al. Among authors: al hallak mn. Future Oncol. 2024 Feb 13. doi: 10.2217/fon-2023-0824. Online ahead of print. Future Oncol. 2024. PMID: 38348690 Free article. Review.
Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis.
Bannoura SF, Aboukameel A, Khan HY, Uddin MH, Jang H, Beal E, Thangasamy A, Kim S, Wagner KU, Mohammad R, Al-Hallak MN, Pasche BC, Azmi AS. Bannoura SF, et al. Among authors: al hallak mn. bioRxiv [Preprint]. 2023 Dec 19:2023.12.18.572102. doi: 10.1101/2023.12.18.572102. bioRxiv. 2023. PMID: 38187605 Free PMC article. Preprint.
Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
Uddin MH, Al-Hallak MN, Khan HY, Aboukameel A, Li Y, Bannoura SF, Dyson G, Kim S, Mzannar Y, Azar I, Odisho T, Mohamed A, Landesman Y, Kim S, Beydoun R, Mohammad RM, Philip PA, Shields AF, Azmi AS. Uddin MH, et al. Among authors: al hallak mn. Clin Transl Med. 2023 Dec;13(12):e1513. doi: 10.1002/ctm2.1513. Clin Transl Med. 2023. PMID: 38131168 Free PMC article.
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura SF, Mzannar Y, Azar I, Beal EW, Tobon ME, Kim SH, Beydoun R, Baloglu E, Senapedis W, El-Rayes BF, Philip PA, Mohammad RM, Shields AF, Al Hallak MN, Azmi AS. Khan HY, et al. Among authors: al hallak mn. Mol Cancer Ther. 2023 Dec 1;22(12):1422-1433. doi: 10.1158/1535-7163.MCT-23-0251. Mol Cancer Ther. 2023. PMID: 37703579 Free PMC article.
Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.
Nagasaka M, Brazel D, Baca Y, Xiu J, Al-Hallak MN, Kim C, Nieva J, Swensen JJ, Spetzler D, Korn WM, Socinski MA, Raez LE, Halmos B, Ou SI. Nagasaka M, et al. Among authors: al hallak mn. Transl Oncol. 2023 Oct;36:101744. doi: 10.1016/j.tranon.2023.101744. Epub 2023 Jul 27. Transl Oncol. 2023. PMID: 37516008 Free PMC article.
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers.
Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura S, Mzannar Y, Azar I, Beal E, Tobon M, Kim S, Beydoun R, Baloglu E, Senapedis W, El-Rayes B, Philip PA, Mohammad RM, Shields AF, Al-Hallak MN, Azmi AS. Khan HY, et al. Among authors: al hallak mn. bioRxiv [Preprint]. 2023 Mar 27:2023.03.27.534309. doi: 10.1101/2023.03.27.534309. bioRxiv. 2023. PMID: 37034616 Free PMC article. Updated. Preprint.
Aberrant transcription factors in the cancers of the pancreas.
Uddin MH, Al-Hallak MN, Philip PA, Chen H, El-Rayes B, Azmi AS. Uddin MH, et al. Among authors: al hallak mn. Semin Cancer Biol. 2022 Nov;86(Pt 2):28-45. doi: 10.1016/j.semcancer.2022.08.011. Epub 2022 Sep 1. Semin Cancer Biol. 2022. PMID: 36058426 Review.
Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY, Nagasaka M, Li Y, Aboukameel A, Uddin MH, Sexton R, Bannoura S, Mzannar Y, Al-Hallak MN, Kim S, Beydoun R, Landesman Y, Mamdani H, Uprety D, Philip PA, Mohammad RM, Shields AF, Azmi AS. Khan HY, et al. Among authors: al hallak mn. Cancer Res Commun. 2022 May;2(5):342-352. doi: 10.1158/2767-9764.crc-21-0176. Epub 2022 May 10. Cancer Res Commun. 2022. PMID: 35573474 Free PMC article.
28 results